Application of Meta-analysis in the Adverse Drug Reaction Signal Detection

Abstract

Abstract: Meta-analysis is a statistical technique for summarizing previous quantitative research with its unique advan-tages. In this article we gave a brief introduction about the concept, steps about meta-analysis. And also illustrated several examples including cardiovascular events caused by TZDs, the incidence of adverse drug reactions(ADR) in hospitalized patients and ethnic differences in risks of adverse reactions. In addition, we also suggested that sensitive analysis, sub-group analysis and model selection should not be ignored while applying Meta-analysis in ADR signal detection.

Key words: Meta-analysis, adverse drug reaction(ADR)

CLC Number:

YE Xiao-fei, QIAN Wei, HE Jia. Application of Meta-analysis in the Adverse Drug Reaction Signal Detection[J]. Chinese Journal of Pharmacovigilance, 2010, 7(3): 148-150.

Add to citation manager EndNote|Ris|BibTeX

URL: https://zgywjj.magtechjournal.com/EN/

https://zgywjj.magtechjournal.com/EN/Y2010/V7/I3/148

References

[1] 周文.药物流行病学[M].1版.北京:人民卫生出版社,2007:7-8.
[2] 詹思延.药物流行病学研究新方法概述-药物流行病学研究新方法系列讲座（一）[J].中国药物应用与监测,2009;6(1):59-62.
[3] 闫永平,陈薇.临床流行病学[M].1版.北京:人民卫生出版社,2009:245.
[4] Lago R M, Singh P P, Nesto R W. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials[J]. Lancet, 2007, 370(9593): 1129-1136.
[5] Singh S, Loke Y K, Furberg C D. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis[J]. JAMA, 2007, 298(10): 1189-1195.
[6] Nissen S E, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes[J]. N Engl J Med, 2007;356(24): 2457-2471.
[7] 中华医学会糖尿病学分会,中华医学会内分泌学分会.中华糖尿病学分会内分泌学分会:关于文迪雅心脏安全性的联合共识[EB/OL]. 2008-5-17 [2009-12-28]. http://www. diab. net.cn / news_show.jsp?id=24.html.
[8] Home P D, Pocock S J, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial [J]. Lancet, 2009, 373(9681):2125-2135.
[9] Loke Y K, Singh S, Furberg C D. Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis[J]. CMAJ, 2009, 180(1): 32-39.
[10] Lazarou J, Pomeranz B H, Corey P N. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies[J]. JAMA, 1998, 279(15): 1200-1205.
[11] McDowell S E, Coleman J J, Ferner R E. Systematic review and meta-analysis of ethnic differences in risks of adverse reactions to drugs used in cardiovascular medicine[J]. BMJ, 2006, 332(7551):1177-1181.
[12] Hernandez A V, Walker E, Ioannidis J P, et al. Challenges in meta-analysis of randomized clinical trials for rare harmful cardiovascular events: the case of rosiglitazone[J]. Am Heart J, 2008,
156(1):23-30.
[13] Rucker G, Schumacher M. Simpson's paradox visualized: the example of the rosiglitazone meta-analysis[J]. BMC Med Res Meth- odol, 2008,8:34.
[14] Shuster J J, Jones L S, Salmon D A. Fixed vs random effects meta-analysis in rare event studies: the rosiglitazone link with myocardial infarction and cardiac death [J]. Stat Med, 2007, 26(24):4375-4385.
[15] Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement[J]. J Clin Epidemiol, 2009,62(10):1006-1012.
[16] Papanikolaou P N, Ioannidis J P. Availability of large-scale evidence on specific harms from systematic reviews of randomized trials[J]. Am J Med, 2004, 117(8):582-589.
[17] Ioannidis J P, Evans S J, Gotzsche P C, et al. Better reporting of harms in randomized trials: an extension of the CONSORT statement [J]. Ann Intern Med, 2004, 141(10):781-788.